HBV-IN-23
HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis[1].
Product Specifications
CAS Number
[2413649-89-3]
UNSPSC
12352005
Target
Apoptosis; DNA/RNA Synthesis; HBV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/hbv-in-23.html
Solubility
10 mM in DMSO
Smiles
CN(CCCOC1=CC=C2N=C(N(C(C2=C1)=O)CC3=CC=CO3)SCC4=CC=CC=C4)C
Molecular Formula
C25H27N3O3S
Molecular Weight
449.57
References & Citations
[1]Qiu J, et al. Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. Eur J Med Chem. 2020 Nov 1;205:112581.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
NFKB1 (KBF1, NF-kappaB, NFkappaB, NF-kB1, NFKB-p50, EBP-1, p50, p105, TRANSCRIPTION FACTOR NFKB1, DNA-binding factor KBF1, NFKB p50, INCLUDED, NFKB p105, INCLUDED, Nuclear factor of kappa light polypeptide gene enhancer in B Cells 1) (PE) discontinued
